Apogee Therapeutics’ anti-IL-13 antibody, APG777, has achieved a 71% reduction in eczema severity after 16 weeks, surpassing the primary endpoint of a phase 2 trial. The study involved 123 adults with moderate-to-severe atopic dermatitis who received either a placebo or a 720-mg dose injection of APG777.
Patients who received APG777 reported a significant improvement in Eczema Area Severity Index (EASI) scores, with 66.9% experiencing a 75% or greater increase compared to 24.6% on placebo. The treatment also showed promise in reducing itchiness by 50.7%.
The results support Apogee’s “exposure-response hypothesis,” which suggests that higher doses of the drug may lead to improved efficacy. The company plans to test higher exposures in a second phase 2 study, expected to start in mid-2026, and a phase 3 trial is pencilled for next year.
Apogee CEO Michael Henderson praised APG777’s potential to set a new standard of care, offering improved clinical responses with potentially transformative quarterly dosing. The company’s stock surged 20% on the news, following Dupixent’s own achievements in treating atopic dermatitis.
Source: https://www.fiercebiotech.com/biotech/apogee-claims-il-13-antibody-sets-new-eczema-treatment-standard-phase-2-study